107 related articles for article (PubMed ID: 10403693)
1. Ifosfamide in malignant mesothelioma: a phase II study.
Andersen MK; Krarup-Hansen A; Mårtensson G; Winther-Nielsen H; Thylen A; Damgaard K; Olling S; Wallin J
Lung Cancer; 1999 Apr; 24(1):39-43. PubMed ID: 10403693
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
3. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Falkson G; Hunt M; Borden EC; Hayes JA; Falkson CI; Smith TJ
Invest New Drugs; 1992 Nov; 10(4):337-43. PubMed ID: 1487409
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
5. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.
Zidar BL; Metch B; Balcerzak SP; Pierce HI; Militello L; Keppen MD; Berenberg JL
Cancer; 1992 Nov; 70(10):2547-51. PubMed ID: 1423183
[TBL] [Abstract][Full Text] [Related]
6. Two dose levels of ifosfamide in malignant mesothelioma.
Içli F; Karaoğuz H; Hastürk S; Kurt B; Akbulut H; Dinçol D; Demirkazik A; Cay F; Akyar S
Lung Cancer; 1996 Sep; 15(2):207-13. PubMed ID: 8882987
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
Dirix LY; van Meerbeeck J; Schrijvers D; Corthouts B; Prové A; van Marck E; Vermeire P; van Oosterom AT
Ann Oncol; 1994 Sep; 5(7):653-5. PubMed ID: 7993844
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
Steele JP; O'Doherty CA; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
Ann Oncol; 2001 Apr; 12(4):497-9. PubMed ID: 11398882
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
10. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Alberts AS; Falkson G; Van Zyl L
J Natl Cancer Inst; 1988 Jul; 80(9):698-700. PubMed ID: 3131539
[No Abstract] [Full Text] [Related]
11. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
12. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
van Meerbeeck JP; Baas P; Debruyne C; Smit EF; van Klaveren RJ; Galdermans D; Lentz MA; Manegold C; Giaccone G;
Eur J Cancer; 2002 Apr; 38(6):779-83. PubMed ID: 11937311
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Palackdharry CS
Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of pirarubicin in malignant pleural mesothelioma.
Kaukel E; Koschel G; Gatzemeyer U; Salewski E
Cancer; 1990 Aug; 66(4):651-4. PubMed ID: 2386894
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of detorubicin in malignant mesothelioma.
Colbert N; Vannetzel JM; Izrael V; Schlienger M; Milleron B; Blanchon F; Herman D; Akoun G; Roland J; Chatelet F
Cancer; 1985 Nov; 56(9):2170-4. PubMed ID: 3902205
[TBL] [Abstract][Full Text] [Related]
17. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
18. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
Astoul P; Picat-Joossen D; Viallat JR; Boutin C
Cancer; 1998 Nov; 83(10):2099-104. PubMed ID: 9827714
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
